九芝堂(000989.SZ):公司部分中成藥產品獲得巴西進口及經營許可
格隆匯9月29日丨九芝堂(000989.SZ)公佈,近日,公司中成藥產品六味地黃丸(濃縮丸)、杞菊地黃丸(濃縮丸)、歸脾丸(濃縮丸)、逍遙丸(濃縮丸)、知柏地黃丸(濃縮丸)、補中益氣丸(小蜜丸)、桂附地黃丸(小蜜丸)七個產品,以“中成藥”品類,獲得了巴西國家衞生監督局(ANVISA)的進口及經營許可備案。
此次公司部分產品獲得巴西國家衞生監督局的進口及經營許可,標誌着上述產品具備了在巴西市場銷售的資格,可以在巴西的醫院、診所、藥店合法銷售。該事項對公司拓展海外市場有積極影響。目前公司海外銷售訂單金額較小,佔公司營業總收入比例較低,對公司經營業績不構成重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.